Skip to main content

Day: December 10, 2021

XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients

CALGARY, Alberta, Dec. 10, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to highlight and announce the online publication of the peer reviewed paper entitled “Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19” in the American Journal of Nephrology and available at the link below. This paper highlights the results of the study that was conducted by the Icahn School of Medicine at Mount Sinai in partnership with XORTX and focused on the clinical outcomes of 834 patients with COVID-19 infection who were hospitalized at Mount Sinai Hospital in New York City. As is typical for COVID-19...

Continue reading

Active Biotech’s nomination committee appointed

In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2021, and the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights. Based on the above, the Nomination Committee is composed with participants representing the largest shareholders in Active Biotech as of September 30, 2021, and consists of: Michael Shalmi, chairmanMats Arnhög, MGA HoldingPer Colleen, 4:e AP FondenPeter Thelin For the 2022 Annual General Meeting, the Nomination Committee shall prepare and submit proposals regarding the Chairman...

Continue reading

Barrick Publishes Human Rights Report

TORONTO, Dec. 10, 2021 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) published its report on Human Rights today outlining the company’s revised policies and standards and their implementation since the merger with Randgold Resources. The publication of the report coincides with the United Nations’ Human Rights Day, which commemorates the day, in 1948, when the UN General Assembly adopted the Universal Declaration of Human Rights. The theme for this year is Equality. During 2020, Barrick updated several standards including the Use of Force Standard and developed a new Voluntary Principles on Security and Human Rights Standard. It also revised, updated and restarted its human rights program, in which every operation conducts a human rights assessment on a two- to three-year cycle. To date, all high- and medium-risk...

Continue reading

IBI Group Announces Acquisition of Solutions Provider, Telenium

Traveller information systems offering complements firm’s SaaS portfolio and adds to its recurring revenue profile TORONTO, Dec. 10, 2021 (GLOBE NEWSWIRE) — Global design and technology firm, IBI Group Inc. (TSX: IBG) (“IBI” or the “Company”), announced today that it has completed the purchase of the assets of Telenium Inc. (“Telenium”), (the “Acquisition”), including all intellectual property and technology assets. Specializing in telecommunications that integrate telephone, computer, and web technologies, Manitoba-based Telenium is most known in Canada for its integrated 511 advanced traveller information solution. The Acquisition bolsters IBI’s Travel-IQ™ product through access to new markets, and increases the firm’s SaaS portfolio and recurring revenue profile. “With IBI now providing SaaS 511 service to nine Canadian provinces...

Continue reading

Laurentian Bank of Canada Announces Normal Course Issuer Bid

MONTREAL, Dec. 10, 2021 (GLOBE NEWSWIRE) — Laurentian Bank of Canada (TSX: LB) (the “Bank”) announced today that it has received the approval of the Toronto Stock Exchange (the “Exchange”) and the Office of the Superintendent of Financial Institutions Canada (OSFI to launch a normal course issuer bid (“NCIB”) to repurchase for cancellation up to 875,000 of its common shares (“Shares”), being approximately 2% of the total number of 43,586,867 Shares outstanding as at December 1, 2021. The actual number of Shares which may be purchased pursuant to the NCIB, and the timing of purchases, will be determined by the Bank. After considering alternative means of distributing excess capital to shareholders, the Bank has concluded that it would be in the best interests of the Bank and its shareholders to implement a NCIB. It is a flexible...

Continue reading

Laurentian Bank of Canada Announces Increased Common Share Dividend

MONTREAL, Dec. 10, 2021 (GLOBE NEWSWIRE) — At its meeting held on December 9, 2021, the Board of Directors of the Laurentian Bank of Canada (TSX: LB) (the “Bank”) has approved an increase of $0.04 on its common shares and declared a regular quarterly dividend of 44 cents per share on the common shares payable on February 1, 2022 to the holders of record at the close of business on January 3, 2022. The above-mentioned dividends are designated as eligible dividends for the purposes of the Income Tax Act (Canada) and any similar provincial and territorial legislation. The Bank’s common shares are eligible shares under the Bank’s Shareholder Dividend Reinvestment and Share Purchase Plan (the “Plan”). Consequently, the holders of such shares may elect to reinvest their dividends in newly issued common shares of the Bank. Under the Plan,...

Continue reading

Getty Images to Become Publicly Traded Company Through Combination with CC Neuberger Principal Holdings II

Getty Images valued at an enterprise value of $4.8 billion Meaningfully reduces leverage and increases cash flow available to further accelerate growth; structure provides certainty of capital at close Getty Images will be listed on the New York Stock Exchange under the ticker symbol “GETY” NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) — Getty Images (the “Company”), a preeminent global visual content creator and marketplace, today announced it has entered into a business combination agreement with CC Neuberger Principal Holdings II (NYSE: PRPB) (“CC Neuberger”), a publicly traded special purpose acquisition company formed through a partnership between CC Capital and Neuberger Berman. Upon closing of the transaction, a newly formed parent company of Getty Images will become a publicly traded company, and its common stock is expected...

Continue reading

DFDS: Financial Calendar 2022

Company Announcement no. 36 / 10 December 2021 DFDS will report and hold the Annual General Meeting (AGM) on the following dates in 2022: Q4 and year-end report 2021                8 February         Deadline for submission ofproposals to the AGM                           8 February         Annual report 2021                            24 February AGM                                                 23 March Q1 report 2022                                 11 May Q2 report 2022                                16 August Q3 report 2022                                17 NovemberMonthly ferry volume updates will be released at around 10.00am CET on the following dates in 2022: 12 January  8 February11 March12 April11 May13 June12 July16 August13 September12 October17 November13 DecemberContact Søren Brøndholt Nielsen, IR +45 33 42...

Continue reading

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 10, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalimab, in multiple disease settings, presented at the European Society for Medical Oncology’s (ESMO) Immuno-Oncology Congress 2021, taking place virtually on December 8-11, 2021. Further details of the poster presentations are as follows:Title: Surufatinib plus toripalimab in patients with advanced small cell lung cancer (SCLC) after failure of 1L systemic chemotherapyFirst Author: Ying Cheng, MD, Jilin Cancer HospitalAbstract No. & Link: 157PDate & Time: Thursday, December 9, 2021, 11:30am – 11:50am CET      Title: Surufatinib plus toripalimab for 2L treatment...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.